View Author
vaccine vaccination infection hepatitis pertussis acellular strategy immunization prevention whole-cell coverage screening acellular vaccine country travel model number hav infection cost-effectiveness result analysis protection traveler whole-cell vaccine region children incidence baseline disease immunity prevalence figure acellular pertussis vaccines assumption ratio hav antibodies 10 years acellular pertussis vaccine attack sensitivity antibody acellular vaccination health virus table compliance group 10- year period duration attack rate traveller europe frequency parameter hepatitis b target group side-e ects adolescent cacy coverage rate hbv infection e cacy epidemiology whole-cell vaccination study torman treatment price baseline assumptions estimate decision cost-effectiveness analysis month scenario intervention saving pediatr european hav infections e ects
5 Most Recent Publications
|
Economic evaluation of pertussis prevention by whole-cell and acellular vaccine in Germany
(Article)
Tormans, G. Clara, R. Doorslaer, E.K.A. van Damme, P. van |
1998-05-28
|
|
Hepatitis B prevention in Europe: a preliminary economic evaluation
(Article)
Damme, P. van Tormans, G. Beutels, P. Doorslaer, E.K.A. van |
1995-01-01
|
|
Cost-effectiveness analysis of vaccination against hepatitus A in travellers
(Article)
Doorslaer, E.K.A. van Tormans, G. Damme, P. van |
1994-12-01
|
|
Recommendations for the prevention of hepatitus A based on a cost-effectiveness analysis
(Article)
Tormans, G. Damme, P. van Doorslaer, E.K.A. van |
1994-01-01
|
|
Cost-effectiveness analysis of hepatitis A prevention in travellers
(Article)
Tormans, G. Damme, P. van Doorslaer, E.K.A. van |
1992-11-26
|
